Bios Equity Partners, LP Increases Stake in Lantern Pharma Inc. to 2.09% via Amendment No. 7

Bios Equity Partners, LP, along with several affiliated entities and individuals including Aaron G.L. Fletcher and Leslie W. Kreis, filed Amendment No. 7 to their Schedule 13D for Lantern Pharma Inc. (LTRN) on May 15, 2026. This filing reports a combined beneficial ownership of 571,305 shares, representing approximately 4.48% of the issuer's common stock based on 12,758,872 shares outstanding. Specifically, Bios Equity Partners, LP (Bios Equity I) is deemed to beneficially own 266,621 shares (2.09%), which are held directly by Bios Fund I, LP, Bios Fund I QP, LP, and BP Directors, LP. The broader reporting group includes various Bios Funds (I and II) and their respective general partners. The shared voting and dispositive power over these securities are managed through a complex structure involving Bios Capital Management, LP and Bios Advisors GP, LLC. This amendment continues to track the group's investment in the Dallas-based pharmaceutical company following previous updates dating back to June 2020.